Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1

Hormone Research

Volumn 65, Issue 1, 2006, Pages 1-5

  Main, Katharina M ^a   Sehested, Astrid ^a   Feldt Rasmussen, Ulla ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Gigantism; Growth hormone; Infancy; Pegvisomant

Indexed keywords

CABERGOLINE; GLYCOSYLATED ALBUMIN; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; ENDOCRINE FUNCTION TEST; FEMALE; GLUCOSE BLOOD LEVEL; GONAD FUNCTION; GROWTH ACCELERATION; GROWTH RATE; HEIGHT; HORMONE BLOOD LEVEL; HUMAN; INTRACRANIAL TUMOR; NEUROFIBROMATOSIS; OPTIC NERVE GLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; THYROID FUNCTION TEST; VELOCITY; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS; BODY HEIGHT; CHILD, PRESCHOOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; NEUROFIBROMATOSIS 1; OPTIC NERVE GLIOMA;

EID: 31744435663     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089486     Document Type: Article

References (22)

1. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ: Growth hormone receptor antagonists: discovery, development and use in patients with acromegaly. Endocr Rev 2002;23:623-646.
2. Trainer PJ: Lessons from 6 years of GH receptor antagonist therapy for acromegaly. J Endocrinol Invest 2003;26(10 suppl):44-52.
3. van der Lely AJ, Hutson K, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759.
4. Andersen E, Andersen H, Hutchings B, Peitersen B, Rosen J, Thamdrup E, Wichmann R, Nyholm M: Højde og vægt hos danske skolebørn 1971-1972. Ugeskr Læger 1974; 136:2796-2802.
5. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179.
6. Bang P, Eriksson U, Sara V, Wivall I-L, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 1991;124:620-629.
7. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR: A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990;70:1292-1298.
8. Juul A, Bang P, Hertel NT, Main KM, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebæk NE: Serum insulin-like growth factor-1 in 1,030 healthy children, adolescents and adults; relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744-752.
9. Juul A, Dalggard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebæk NE: Serum levels of insulin-like growth factor (IGF) binding protein-3 in healthy infants, children and adolescents: the relation to IFD-I, IGF-II, IGF-BP1, IGF-BP2, age, sex, body mass index and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-2542.
10. Asa SL, Bilbao JM, Kovacs K, Linfoot JA: Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegaly. Acta Neuropathol 1980;52:231-234.
11. Duchowny MS, Katz R, Bejar RL: Hypothalamic mass and gigantism in neurofibromatosis: treatment with bromocriptin. Ann Neurol 1984;5:302-304.
12. Drimmie FM, MacLennan AC, Nicoll JA, Simpson E, McNeill E, Donaldson MD: Gigantism due to growth hormone excess in a boy with optic glioma. Clin Endocrinol 2000;53:535-538.
13. Ritzen EM, Wettrell G, Davies G, Grant DB: Management of pituitary gigantism. The role of bromocriptin and radiotherapy. Acta Paediatr 1985;74:807-814.
14. Christensen SE, Weeke J, Orskov H, Moller N, Flybjerg A, Harris AG, Lund E, Jørgensen J: Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol 1987;27:297-306.
15. Näntö-Salonen K, Koskinen P, Sonninen P, Toppari J: Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy. Acta Paediatr 1999;88:29-33.
16. De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton CN: Pituitary adenoma in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest 2001;24:92-97.
17. Abe T, Tara LA, Ludecke DK: Growth hormone-secreting pituitary adenomas in childhood adolescence: features and results of transnasal surgery. Neurosurgery 1999;45:1-10.
18. Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, Sainte-Rose C, Dellatolas G, Raquin MA, Jambaque I, Kalifa C: Long-term intellectual outcome in children with posterior fossa tumours according to radiation dose and volumes. Int J Radiat Oncol Biol Phys 1999;45:137-145.
19. Listernick R, Charrow J, Greenwald M, Mets M: Natural history of optic pathway tumours in children with neurofibromatosis type I: a longitudinal study. J Pediatr 1994;127:507-508.
20. Grill J, Laithier V, Rodrigues D, Raquin MA, Pierre-Kahn A, Kalifa C: When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 2000;59:692-696.
21. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B: Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol 2005;153:195-201.
22. Jehle S, Reyes CM, Sundeen RE, Freda PU: Alternate-day administration of pegvisomant maintains normal serum IGFI levels in patients with acromegaly. J Clin Endocrinol Metab 2005;90:1588-1593.